{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T22:23:03Z","timestamp":1776550983691,"version":"3.51.2"},"reference-count":45,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A2C1011350"],"award-info":[{"award-number":["2019R1A2C1011350"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI15C2796"],"award-info":[{"award-number":["HI15C2796"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Breast cancer resistance protein (BCRP) mediates pharmacokinetic drug interactions. This study evaluated the potential of quercetin to inhibit and induce BCRP in vitro and in vivo. The inhibition of BCRP was investigated for quercetin and its metabolites using BCRP\/mBcrp1-overexpressing MDCKII cells by flow cytometry. The induction of BCRP was investigated in LS174T cells using quantitative PCR. The expression of rat BCRP in rat small intestine, liver, and kidney was also measured after multiple administrations of quercetin in rats (50, 100, and 250 mg\/kg, seven days). The in vivo pharmacokinetic changes of sulfasalazine following single or multiple administration of quercetin in rats and beagles were investigated. Although the induction effect of quercetin on BCRP was observed in vitro, the in vivo expression of rat BCRP was not changed by multiple quercetin administrations. Oral administration of quercetin did not affect the plasma concentration or pharmacokinetic parameters of sulfasalazine, regardless of dose and dosing period in either rats or beagles. In addition, the inhibitory effect of quercetin metabolites on BCRP\/mBcrp1 was not observed. These results suggest that the in vivo drug interaction caused by quercetin via BCRP was negligible, and it may be related to the metabolic inactivation of quercetin for the inhibition of BCRP.<\/jats:p>","DOI":"10.3390\/pharmaceutics13121989","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:22:56Z","timestamp":1638314576000},"page":"1989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Negligible Effect of Quercetin in the Pharmacokinetics of Sulfasalazine in Rats and Beagles: Metabolic Inactivation of the Interaction Potential of Quercetin with BCRP"],"prefix":"10.3390","volume":"13","author":[{"given":"Ju-Hee","family":"Oh","sequence":"first","affiliation":[{"name":"Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dokeun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haejun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeonghee","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taehoon","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-8895","authenticated-orcid":false,"given":"Min Chang","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-3175","authenticated-orcid":false,"given":"Young-Joo","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/17425255.2010.529129","article-title":"Herb\u2013drug pharmacokinetic interactions reviewed","volume":"6","author":"Tarirai","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2125.2006.02797.x","article-title":"Clinical risk management of herb-drug interactions","volume":"63","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40005-021-00515-1","article-title":"Intestinal membrane transporter-mediated approaches to improve oral drug delivery","volume":"51","author":"Pangeni","year":"2021","journal-title":"J. Pharm. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.ki.5002645","article-title":"The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane","volume":"73","author":"Huls","year":"2008","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: A perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1476-5381.2012.01887.x","article-title":"Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of bcrp","volume":"166","author":"Kusuhara","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0002-8223(02)90314-7","article-title":"Flavonol and Flavone Intakes in US Health Professionals","volume":"102","author":"Sampson","year":"2002","journal-title":"J. Am. Diet. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.fct.2007.05.015","article-title":"A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic\/carcinogenic properties","volume":"45","author":"Harwood","year":"2007","journal-title":"Food Chem. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0076-6879(90)86128-I","article-title":"[36] Flavonoids as antioxidants: Determination of radical-scavenging efficiencies","volume":"186","author":"Bors","year":"1990","journal-title":"Methods Enzymol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/ptr.6382","article-title":"Dietary quercetin supplements: Assessment of online product informations and quantitation of quercetin in the products by high-performance liquid chromatography","volume":"33","author":"Vida","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.lfs.2003.06.044","article-title":"Lethal quercetin-digoxin interaction in pigs","volume":"74","author":"Wang","year":"2004","journal-title":"Life Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.biopha.2006.07.081","article-title":"Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients","volume":"60","author":"Brand","year":"2006","journal-title":"Biomed. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbrc.2004.03.040","article-title":"Interaction of the breast cancer resistance protein with plant polyphenols","volume":"317","author":"Cooray","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/mol.65.5.1208","article-title":"Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport","volume":"65","author":"Zhang","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1124\/mol.104.009753","article-title":"Breast cancer resistance protein (bcrp1\/abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides","volume":"67","author":"Sesink","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_16","first-page":"25","article-title":"Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid","volume":"4","author":"Yoshikawa","year":"2004","journal-title":"J. Exp. Ther. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Song, Y.-K., Yoon, J.-H., Woo, J.K., Kang, J.-H., Lee, K.-R., Oh, S.H., Chung, S.-J., and Maeng, H.-J. (2020). Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12050397"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32167","DOI":"10.1074\/jbc.273.48.32167","article-title":"Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain","volume":"273","author":"Bakos","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/jpet.104.073916","article-title":"Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine","volume":"312","author":"Pavek","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/jnci\/92.20.1651","article-title":"Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan","volume":"92","author":"Jonker","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bdd.639","article-title":"Changes in mRNA expression of ABC and SLC transporters in liver and intestines of the adjuvant-induced arthritis rat","volume":"30","author":"Uno","year":"2009","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.phrs.2008.01.006","article-title":"ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells","volume":"57","author":"Bihorel","year":"2008","journal-title":"Pharmacol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1124\/dmd.107.019943","article-title":"Metabolism and Transport of the Citrus Flavonoid Hesperetin in Caco-2 Cell Monolayers","volume":"36","author":"Brand","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ajps.2018.12.003","article-title":"Evaluation of the Mrp2-mediated flavonoid-drug interaction potential of quercetin in rats and in vitro models","volume":"14","author":"Oh","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1083\/jcb.43.3.506","article-title":"High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural study","volume":"43","author":"Berry","year":"1969","journal-title":"J. Cell Biol."},{"key":"ref_26","first-page":"e3917","article-title":"Isolation and Primary Culture of Rat Hepatic Cells","volume":"64","author":"Shen","year":"2012","journal-title":"J. Vis. Exp."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0005-2736(01)00308-X","article-title":"A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)","volume":"1512","author":"Robey","year":"2001","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res."},{"key":"ref_29","first-page":"105","article-title":"Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists","volume":"2","author":"Tsukahara","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1124\/dmd.112.046508","article-title":"Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics","volume":"40","author":"Bedwell","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/FPC.0b013e3282f974dc","article-title":"Breast cancer resistance protein (ABCG2) and drug disposition: Intestinal expression, polymorphisms and sulfasalazine as an in vivo probe","volume":"18","author":"Urquhart","year":"2008","journal-title":"Pharm. Genom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/mp050113v","article-title":"Breast Cancer Resistance Protein (Bcrp\/abcg2) Is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse","volume":"3","author":"Zaher","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_33","first-page":"424","article-title":"Minor effects of the Citrus flavonoids naringin, naringenin and quercetin, on the pharmacokinetics of doxorubicin in rats","volume":"66","author":"Park","year":"2011","journal-title":"Pharmazie"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1248\/bpb.32.497","article-title":"Kinetic Characterization of Sulfasalazine Transport by Human ATP-Binding Cassette G2","volume":"32","author":"Jani","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1124\/dmd.108.020859","article-title":"Closing the Gaps: A Full Scan of the Intestinal Expression of P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance-Associated Protein 2 in Male and Female Rats","volume":"36","author":"MacLean","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.1982.tb01415.x","article-title":"The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man","volume":"13","author":"Azadkhan","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1023\/A:1015938706685","article-title":"Pharmacokinetics of Sulfasalazine Metabolites in Rats Following Concomitant Oral Administration of Riboflavin","volume":"6","author":"Chungi","year":"1989","journal-title":"Pharm. Res."},{"key":"ref_38","first-page":"G120","article-title":"Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen","volume":"277","author":"Crespy","year":"1999","journal-title":"Am. J. Physiol. Content"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1079\/BJN20061809","article-title":"Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions","volume":"96","author":"Mullen","year":"2006","journal-title":"Br. J. Nutr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00394-015-0862-9","article-title":"Comparing the metabolism of quercetin in rats, mice and gerbils","volume":"55","author":"Yeh","year":"2015","journal-title":"Eur. J. Nutr."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mohos, V., Flisz\u00e1r-Ny\u00fal, E., Ungv\u00e1ri, O., Kuffa, K., Needs, P.W., Kroon, P.A., Telbisz, \u00c1., \u00d6zvegy-Laczka, C., and Po\u00f3r, M. (2020). Inhibitory Effects of Quercetin and Its Main Methyl, Sulfate, and Glucuronic Acid Conjugates on Cytochrome P450 Enzymes, and on OATP, BCRP and MRP2 Transporters. Nutrients, 12.","DOI":"10.3390\/nu12082306"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/jf010919h","article-title":"Quercetin, but not Its Glycosides, Is Absorbed from the Rat Stomach","volume":"50","author":"Crespy","year":"2002","journal-title":"J. Agric. Food Chem."},{"key":"ref_43","first-page":"2599","article-title":"Quercetin3obetadglucoside decreases the bioavailability of cyclosporin a through regulation of drug metabolizing enzymes, transporters and nuclear receptors in rats","volume":"18","author":"Yang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tox.2017.02.012","article-title":"In vitro inhibition of human CYP2E1 and CYP3A by quercetin and myricetin in hepatic microsomes is not gender dependent","volume":"381","author":"Zamaratskaia","year":"2017","journal-title":"Toxicology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11481-006-9034-2","article-title":"MDR- and CYP3A4-Mediated Drug\u2013Drug Interactions","volume":"1","author":"Pal","year":"2006","journal-title":"J. Neuroimmune Pharmacol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/1989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:50Z","timestamp":1760168090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/1989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pharmaceutics13121989"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13121989","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]}}}